Evidence map›Paper›PMID 31618913›Full record

ArticleInternational journal of environmental research and public health2019

Skin Melanoma and Subsequent Risk of Prostate Cancer: A Lithuanian Cancer Registry Study.

Ausvydas Patasius, Vincas Urbonas, Giedre Smailyte

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ausvydas PatasiusLaboratory of Cancer Epidemiology, National Cancer Institute, Santariskiu 1, LT-08660 Vilnius, Lithuania. ausvydas.patasius@nvi.lt.ORCID 0000-0003-3874-2723
Vincas UrbonasLaboratory of Clinical Oncology, National Cancer Institute, Santariskiu 1, LT-08660 Vilnius, Lithuania.ORCID 0000-0002-8070-6163
Giedre SmailyteLaboratory of Cancer Epidemiology, National Cancer Institute, Santariskiu 1, LT-08660 Vilnius, Lithuania. giedre.smailyte@nvi.lt.ORCID 0000-0001-8365-543X
Vilnius University · LTNational Cancer Institute · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging data indicates that melanoma may be linked to prostate cancer. We evaluated if the incidence of melanoma was associated with subsequent risk of prostate cancer (PC). We extracted data from the Lithuanian cancer registry from 1993 to 2012. We calculated the standardized incidence ratios (SIRs) for PC as a ratio of observed number of cancer cases in people with previous melanoma diagnosis to the expected number of cancer cases in the underlying general population. Therein, 95% confidence intervals for the SIRs were estimated assuming the number of observed cancer cases follows the Poisson distribution. Overall, 65 PCs were observed versus 52.5 expected (SIR 1.24; 95% CI: 0.97-1.58) within a period of 24 years. A significantly increased risk of PC was found in patients with melanoma diagnosis over 70 years (SIR 1.62; 95% CI: 1.11-2.39) and in two periods of diagnosis (SIRs 1.76 and 1.62 in 1993-1997 and 2009-2012, respectively). A significantly increased risk was also found five to nine years after melanoma diagnosis (SIR 1.58; 95% CI: 1.05-2.38). Further studies are needed to evaluate the relationship between melanoma and subsequent risk of prostate cancer.

Indexed as

AgedHumansIncidenceLithuaniaMaleMelanomaMiddle AgedProstatic NeoplasmsRegistriesSkin Neoplasmscancer registryepidemiologymelanomaprostate cancer

Identifiers

PMID31618913
PMCPMC6843351
OpenAlexW2980322975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.